Avidity Biosciences Receives Buy Rating and $55 Price Target from Goldman Sachs

Retrieved on: 2025-07-11 12:04:51

Tags for this article:

Click the tags to see associated articles and topics

Avidity Biosciences Receives Buy Rating and $55 Price Target from Goldman Sachs. View article details on hiswai:

Excerpt

... Antibody Oligonucleotide Conjugates (AOC). The company combines the tissue selectivity of monoclonal antibodies with the precision of ...

Article found on: www.ainvest.com